Get the Stockscreener App
1.09
2.68%
-0.03
Neurosense Therapeutics Ltd stock is traded at $1.09, with a volume of 121.30K.
It is down -2.68% in the last 24 hours and down -12.80% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.12
Open:
$1.13
24h Volume:
121.30K
Relative Volume:
0.20
Market Cap:
$28.05M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.8658
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-4.39%
1M Performance:
-12.80%
6M Performance:
+5.83%
1Y Performance:
-14.17%
1-Day Range:
$1.07
$1.1383
1-Week Range:
$1.03
$1.16
52-Week Range:
$0.80
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.085 | 28.05M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
What momentum indicators show for NeuroSense Therapeutics Ltd. stockBear Alert & Verified Swing Trading Watchlists - newser.com
Real time scanner hits for NeuroSense Therapeutics Ltd. Equity Warrant explainedExit Point & Expert Approved Momentum Ideas - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersJuly 2025 Outlook & Fast Exit/Entry Strategy Plans - newser.com
NeuroSense (NASDAQ: NRSN) sets Dec. 8, 2025 investor webinar on ALS PARAGON, Canada NOC/c - Stock Titan
Tick level data insight on NeuroSense Therapeutics Ltd. Equity Warrant volatilityWeekly Profit Summary & Daily Volume Surge Trade Alerts - newser.com
Analyzing NeuroSense Therapeutics Ltd. Equity Warrant with multi timeframe chartsIPO Watch & Reliable Breakout Forecasts - newser.com
Key metrics from NeuroSense Therapeutics Ltd. Equity Warrant’s quarterly data2025 Key Lessons & Risk Controlled Stock Alerts - newser.com
Can volume confirm reversal in NeuroSense Therapeutics Ltd.Earnings Risk Report & AI Driven Stock Reports - newser.com
Tools to monitor NeuroSense Therapeutics Ltd. recovery probabilityTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
How to use a screener to detect NeuroSense Therapeutics Ltd. Equity Warrant breakoutsCEO Change & Safe Capital Preservation Plans - newser.com
Will NeuroSense Therapeutics Ltd. Equity Warrant stock attract more institutional investorsJuly 2025 PreEarnings & Precise Swing Trade Entry Alerts - newser.com
Using Ichimoku Cloud for NeuroSense Therapeutics Ltd. Equity Warrant technicalsProfit Target & Consistent Return Investment Signals - newser.com
How institutional ownership impacts NeuroSense Therapeutics Ltd. stockJuly 2025 Short Interest & Capital Efficiency Focused Strategies - newser.com
Signal strength of NeuroSense Therapeutics Ltd. stock in tech scannersVolume Spike & Weekly Watchlist of Top Performers - newser.com
Key metrics from NeuroSense Therapeutics Ltd.’s quarterly data2025 Retail Activity & Long-Term Safe Investment Plans - newser.com
Is NeuroSense Therapeutics Ltd. stock a safe haven assetJuly 2025 Trends & Low Risk Growth Stock Ideas - newser.com
Can NeuroSense Therapeutics Ltd. hit a new high this month2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
Visual analytics tools that track NeuroSense Therapeutics Ltd. performanceQuarterly Growth Report & Verified Swing Trading Watchlist - newser.com
What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockCEO Change & Daily Profit Maximizing Tips - newser.com
Tools to monitor NeuroSense Therapeutics Ltd. Equity Warrant recovery probability2025 Pullback Review & AI Driven Stock Reports - newser.com
Multi factor analysis applied to NeuroSense Therapeutics Ltd. Equity WarrantJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs in stagflation2025 Retail Activity & Real-Time Price Movement Reports - newser.com
Using RSI to spot recovery in NeuroSense Therapeutics Ltd.Weekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Visualizing NeuroSense Therapeutics Ltd. stock with heatmapsJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - newser.com
Using data tools to time your NeuroSense Therapeutics Ltd. Equity Warrant exitJuly 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com
Is NeuroSense Therapeutics Ltd. showing signs of accumulation2025 Analyst Calls & Safe Entry Point Alerts - newser.com
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs in high volatility marketsEarnings Growth Report & Verified Technical Signals - newser.com
What sentiment indicators say about NeuroSense Therapeutics Ltd. stockPortfolio Gains Summary & Daily Chart Pattern Signals - newser.com
Why NeuroSense Therapeutics Ltd. (H1Z) stock attracts wealthy investorsInsider Buying & Safe Capital Allocation Plans - newser.com
Using R and stats models for NeuroSense Therapeutics Ltd. Equity Warrant forecasting2025 Top Decliners & Low Risk Growth Stock Ideas - newser.com
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):